Liminal BioSciences Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative treatments for patients with unmet medical needs, particularly focusing on rare and orphan diseases. The company operates through two main segments: Small Molecule Therapeutics and Plasma Derived Therapeutics. Its lead product candidate, fezagepras, targets idiopathic pulmonary fibrosis, respiratory diseases, and Alström Syndrome. In the Plasma Derived Therapeutics segment, Liminal BioSciences offers a Plasma Protein Purification System for extracting and purifying therapeutic proteins from human plasma and is developing Ryplazim for congenital plasminogen deficiency. Founded in 1992 and headquartered in Laval, Quebec, the company has a presence in Canada, the United Kingdom, and the United States. It was previously known as Prometic Life Sciences Inc. before rebranding in October 2019.
Fairhaven Pharmaceuticals is a developer of oral therapeutics intended to treat severe inflammatory conditions. The company offers a preclinical research program of small molecule antagonists and other related services to develop oral therapeutics, enabling clinicians to treat patients with inflammatory conditions.
Telesta Therapeutics is a Canadian biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative therapeutics aimed at addressing significant unmet medical needs, primarily in oncology. The company is focused on creating novel medicines that can transform the treatment landscape for serious diseases, including cancer and immune disorders. Its lead product, MCNA, has successfully completed a Phase III pivotal study for patients with non-muscle invasive bladder cancer who have not responded to initial treatment with bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application to the U.S. FDA in June 2015 and aims to provide MCNA to patients and healthcare providers pending approval. Ultimately, the company seeks to enhance the quality of life and extend survival for individuals affected by bladder cancer, one of the most prevalent cancers today.
Pathogen Removal and Diagnostic Technologies
Acquisition in 2008
Pathogen Removal and Diagnostic Technologies, Inc. engages in development of products and devices that remove and detect different pathogens from biological sources. The company was founded in 2002 and is based in Washington, District Of Columbia. Pathogen Removal and Diagnostic Technologies Inc. operates as a subsidiary of American Red Cross, The.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.